Biotech’s Uncomfortable Adolescence: Capital Is Back, But the Industry Has Changed Permanently
Biotech VC hit $26B in 2024 as IPOs lagged and China licensing surged—here's what the recovery's structure reveals about...
venture capital
Europe’s Biotech Execution Gap Demands Capital Reform and Regulatory Harmony
At BIO-Europe Spring 2026 in Lisbon, investors and pharma executives diagnosed Europe's biotech bottleneck not as a science deficit...